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 SYMPOSIUM: NEW ICRU REPORTS AND HOW THEY 
ARE CHANGING PRACTICE…  
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ICRU 50 and ICRU 62 documents established recommendations and 
procedures for the practice of Two-Dimensional Radiation Therapy 
(2D-RT) and to a lesser extent, Three-Dimensional Conformal 
Radiation Therapy (3D-CRT). Some of these recommendations were 
however only concepts, which, although extremely valid, were 
impractical to implement in modern radiotherapy.  In addition, new 
concepts to account for the practice of Intensity-Modulated Radiation 
Therapy (IMRT) were required. In this framework, ICRU 83 provides 
updates to the earlier documents to take into account changes in 
practice with IMRT and evolving improved practice in 3D-CRT. 
IMRT and 3D-CRT required the use of accurate guidelines for the 
selection and delineation of the various target volumes on a 
volumetric basis. In addition, various imaging modalities (including 
molecular imaging) may be used for planning not only before the start 
of treatment, but also during treatment to adapt the dose 
distribution.The concepts of gross tumor volume (GTV) and clinical 
target volume (CTV) have been crucial conceptually, but 
recommendations for outlining were needed for a practical 
implementation on a daily basis. Refinement for OAR delineation 
(e.g."tube" organs, "parallel-like or serial-like) were also provided. 
The IMRT planning process uses an optimizer, which expresses the 
radiation oncologist’s treatment goals.  The committee has designated 
the set of optimizer parameters the “planning aims” to differentiate 
from the usual meaning of “prescription”. Multiple recent publications 
have pointed out that the choice for planning target volume (PTV) 
margin should be based on clinical QA measurements and should place 
more emphasis on systematic uncertainties as they have more impact 
on the accuracy of dose delivered to the patient as compared to 
random uncertainties. Unlike 3D-CRT, IMRT does not deliver dose to 
all of the target volume a tone time.  IMRT delivered to moving organs 
may allow hot and cold spots to develop in the CTV even though a 
generous PTV margin has been drawn. IMRT has gained prominence 
because it allows a lower dose to neighboring sensitive normal tissues 
even though it may result in less dose homogeneity to the tumor.  
Therefore, the use of a single reference point for prescription and 
reporting recommended in earlier protocols can lead to unnecessary 
dose uncertainty and so the committee  recommended dose-volume 
reporting, for example, the dose which covers some high fraction of 
the target volume as preferable. Last, the implementation of IMRT 
requires adequate quality control of the equipment as well as of any 
individual plan to ensure proper dose delivery in accordance with the 
presciption. 
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The new joint ICRU/GEC ESTRO report (88, 2013) reflects and further 
structures the on-going developments in the field of IGABT and was 
preceded by 4 GEC ESTRO recommendations on adaptive target 
concepts, dose volume parameters, biological modelling, applicator 
reconstruction and imaging. They have become widely accepted in the 
international community and have become the basis of this report.  
The current report focuses on the volumetric image guided adaptive 
approach. It also includes traditional 2D planning which is linked to 
the 3D world by recommending point A.  
The GTV and CTV concepts follow the ICRU tradition with a special 
focus on the change of CTV during treatment. The High Risk CTV is 
introduced which represents residual GTV and surrounding are 
assumed to carry a high risk for residual cancer cells after 40-45 Gy 
EBRT plus chemotherapy and always the whole cervix. An additional 
Intermediate Risk CTV is suggested representing the area of tumour 
spread at diagnosis and a margin around the CTVHR. Uncertainties for 
GTV/CTV selection and contouring are recognized as due to internal 
motion and applicator reconstruction and discussed in the frame of 
intracavitary brachytherapy. The addition of margins (as in EBRT) is 
discouraged (dose escalation).  PTV has to be designed when planning 
the application which has to be adapted as appropriate.  
For adjacent OARs rectum, bladder and sigmoid 2cm³ and 0.1 cm³ are 
defined as reference. For the vagina anatomical reference points are 
recommended due to contouring and dosimetric uncertainties. 
Uncertainties due to internal motion are recognized for OARs and 
corrected through repetitive imaging. 
Dose (rate) per fraction is recommended to be reported as physical 
dose and calculated and reported as iso-effective dose in EQD2 
following the LQ model. Its pragmatic use is encouraged for treatment 
planning withan α/β value of 10 Gy for tumour and 3 Gy for OAR 
although its limitations are recognized. 
For the target the main dose volume parameter is D90, complemented 
by D98 as near-minimum dose and D50 indicating the high dose 
volume. Dose variation is around 200%.  
Point A is encouraged to be continued for dose reporting, clearly 
defined based on the applicator geometry. It will allow reproducible 
dose assessment for the 2D approach, but also consistency and 
comparability for the 3D approach. The TRAK remains an essential 
reporting parameter.  
For normal tissues D2cm³ and D0.1cm³ are the main parameters for 
the 3D approach. Additional  parameters for the mid and low dose 
region arediscussed, mainly reflecting EBRT. Applicator related points 
are recommended for the upper vagina (at 0/5 mm (ABS)) and 
anatomy related points for the mid and low vagina. For the 2D 
approach the dose points for rectum and bladder remain as defined in 
ICRU 38.  
The report also contains recommendations and information on 
treatment planning, applicator reconstruction, 3D dose summation, 
source strength specification and dose calculation.  
“Planning aim” (ICRU 83) is also introduced for brachytherapy 
treatment planning and represents a certain “treatment schedule” for 
a specific clinical scenario including a set of dose and volume 
parameters fora specific applicator. During the treatment planning 
optimization, adaptations are performed according to dose volume 
constraints for the target and OARs. “Prescription” is based on the 
final set of parameters which presents the treatment plan finally used 
for irradiation.  
The upcoming report is based on concepts and terms developed within 
the frame of the on-going technical and clinical developments. The 
terms support the transition from 2D to 3D/4D gynaecologic 
brachytherapy and have become integrated into the educational 
programmes of leading international Societies. They are being 
clinically validated in a spreading number of centres in Europe and 
worldwide. Research validation is on-going within various multi-centre 
trials (e.g. EMBRACE) which will help to define the”true” clinical 
value, reliability and reproducibility. These evaluations may require 
further adaptations.   
   
 
 
 
 
 
 
 
 
 
